Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A

Executive Summary

Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.

You may also be interested in...



Janssen Oncology Strategy: Take A Holistic Approach To R&D

With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.

J&J/Genmab’s Darzalex Leads Way For Anti-CD38 Antibodies in Myeloma

Speedy even by the standards of accelerated approval, FDA’s clearance of first-in-class daratumumab in salvage setting gives hope for broader ambitions in myeloma and beyond.

Deal Watch: Immuno-Oncology Collaborations Keep Piling Up

AstraZeneca and Genentech sign agreements with a number of firms with promising early stage assets, with Bristol looking to spread reach into rare cancers; J&J joins the game. Drama continues to unfold for Mylan/Perrigo, Shire/Baxalta and Horizon/Depomed.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS056905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel